Document Detail


Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players?
MedLine Citation:
PMID:  16837083     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cyclooxygenase-2 (COX-2) inhibitors dilemma in cardiovascular medicine has not been resolved yet. The cardiovascular safety of selective COX-2 inhibitors other than rofecoxib is uncertain. Given the ongoing controversy surrounding the use of COX-2 inhibitors, further clinical studies with different types of drugs are required to establish safety and therapeutic benefit in patients with coronary artery disease.
Authors:
Turgay Celik; Atila Iyisoy; Hurkan Kursaklioglu; U Cagdas Yuksel
Related Documents :
17172923 - Association of rage gene polymorphisms with coronary artery disease in the korean popul...
1572743 - Gated technetium-99m methoxy-isobutylisonitrile perfusion imaging.
9068403 - Pulmonary atresia, "intact ventricular septum", and aortopulmonary collateral arteries.
Publication Detail:
Type:  Comment; Letter     Date:  2006-07-11
Journal Detail:
Title:  International journal of cardiology     Volume:  116     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-19     Completed Date:  2007-03-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  259-60     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular System / drug effects*
Cyclooxygenase 2 Inhibitors / adverse effects*,  therapeutic use*
Humans
Chemical
Reg. No./Substance:
0/Cyclooxygenase 2 Inhibitors
Comments/Corrections
Comment On:
Int J Cardiol. 2006 Oct 10;112(3):359-66   [PMID:  16330117 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Electrocardiographic exercise stress testing: an update beyond the ST segment.
Next Document:  Autoimmunity in myocardial infarction.